Literature DB >> 22504871

Small interfering RNA targeting HMGN5 induces apoptosis via modulation of a mitochondrial pathway and Bcl-2 family proteins in prostate cancer cells.

Xiao-Yu Zhang1, Zhong-Qiang Guo, Shi-Qi Ji, Min Zhang, Ning Jiang, Xue-Song Li, Li-Qun Zhou.   

Abstract

We investigated the importance of HMGN5, a nuclear protein that binds to nucleosomes, unfolds chromatin, and affects transcription, in the LNCaP prostate cancer cell line. We also examined the molecular mechanisms that promote apoptosis of LNCaP cells after infection with small interfering RNA (siRNA) targeting HMGN5 (siRNA-HMGN5). The androgen-dependent LNCaP human prostate cancer cells were infected with siRNA-HMGN5. Apoptosis was detected using the Annexin V-PE/7-AAD double staining and the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assays. Mitochondrial membrane potential was measured by JC-1 staining. HMGN5 and GAPDH mRNA expression were determined using real-time PCR. Bcl-2 and other apoptosis-related protein levels were determined by Western blot analysis. Caspase activity was measured by cleavage of the caspase substrate. Infection with siRNA targeting HMGN5 efficiently and specifically reduced the HMGN5 expression in LNCaP cells. The downregulation of HMGN5 induced remarkable apoptosis of LNCaP cells and resulted in the reduction of mitochondrial membrane potential. The induction of cell apoptosis was accompanied by the upregulation of Bax, the Bax/Bcl-2 ratio and the activation of caspase3. The HMGN5-targeted siRNA was effective in downregulating the expression of HMGN5 in androgen-dependent prostate cancer cells and inducing cell apoptosis via the regulation of a caspase-related mitochondrial pathway and Bcl-2 family proteins. This study suggests that HMGN5 may be a potential molecular target with therapeutic relevance for the treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504871      PMCID: PMC3720167          DOI: 10.1038/aja.2012.18

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  27 in total

Review 1.  RNA interference and the use of small interfering RNA to study gene function in mammalian systems.

Authors:  I Bantounas; L A Phylactou; J B Uney
Journal:  J Mol Endocrinol       Date:  2004-12       Impact factor: 5.098

Review 2.  RNA interference for the treatment of cancer.

Authors:  Lisa N Putral; Wenyi Gu; Nigel A J McMillan
Journal:  Drug News Perspect       Date:  2006 Jul-Aug

Review 3.  The changing face of prostate cancer.

Authors:  Matthew R Cooperberg; Judd W Moul; Peter R Carroll
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

4.  HMGN5: a potential oncogene in gliomas.

Authors:  Jintao Qu; Runmin Yan; Juxiang Chen; Tao Xu; Jingxu Zhou; Mei Wang; Chao Chen; Yong Yan; Yicheng Lu
Journal:  J Neurooncol       Date:  2011-03-04       Impact factor: 4.130

Review 5.  Cancer of the prostate.

Authors:  Sergio Bracarda; Ottavio de Cobelli; Carlo Greco; Tommaso Prayer-Galetti; Riccardo Valdagni; Gemma Gatta; Filippo de Braud; Georg Bartsch
Journal:  Crit Rev Oncol Hematol       Date:  2005-12       Impact factor: 6.312

6.  NBP-45, a novel nucleosomal binding protein with a tissue-specific and developmentally regulated expression.

Authors:  H Shirakawa; D Landsman; Y V Postnikov; M Bustin
Journal:  J Biol Chem       Date:  2000-03-03       Impact factor: 5.157

7.  A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference.

Authors:  Douglas A Rubinson; Christopher P Dillon; Adam V Kwiatkowski; Claudia Sievers; Lili Yang; Johnny Kopinja; Dina L Rooney; Mingdi Zhang; Melanie M Ihrig; Michael T McManus; Frank B Gertler; Martin L Scott; Luk Van Parijs
Journal:  Nat Genet       Date:  2003-02-18       Impact factor: 38.330

8.  Characterization of a human gene encoding nucleosomal binding protein NSBP1.

Authors:  L M King; C A Francomano
Journal:  Genomics       Date:  2001-01-15       Impact factor: 5.736

9.  High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells.

Authors:  V Boonyaratanakornkit; V Melvin; P Prendergast; M Altmann; L Ronfani; M E Bianchi; L Taraseviciene; S K Nordeen; E A Allegretto; D P Edwards
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

10.  Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours.

Authors:  J Green; M Ikram; J Vyas; N Patel; C M Proby; L Ghali; I M Leigh; E A O'Toole; A Storey
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

View more
  3 in total

Review 1.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 2.  Research advances in HMGN5 and cancer.

Authors:  Zhan Shi; Run Tang; Ding Wu; Xiaoqing Sun
Journal:  Tumour Biol       Date:  2015-12-23

3.  HMGN5 Silencing Suppresses Cell Biological Progression via AKT/MAPK Pathway in Human Glioblastoma Cells.

Authors:  Quanfeng Ma; Xiuyu Wang; Hong Wang; Wen Song; Qiong Wang; Jinhuan Wang
Journal:  Biomed Res Int       Date:  2020-05-21       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.